Does stem cell therapy cure kidney disease?

The goal of regenerative treatment is different: to support the body's repair mechanisms, reduce chronic inflammation and improve quality of life, alongside your nephrology care. Research supports this approach. A 2025 systematic review and meta-analysis in Cells found that mesenchymal stem cells (MSCs) improved kidney function and reduced inflammation in animal models of CKD, and in both animal and human studies they significantly reduced protein leakage in the urine, a marker linked to the risk of disease progression. At Stem Cell Mexico, kidney protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, given by intravenous (IV) infusion after a review of your recent blood work. Some patients report better energy and well-being, results vary between individuals, and progress is followed with repeat lab tests.

This guide explains why CKD is a chronic condition, what regenerative treatment can realistically support, how it fits with proven kidney care and how to decide whether it makes sense for you.

Understanding chronic kidney disease

The kidneys filter waste and excess fluid from the blood, balance electrolytes such as sodium and potassium, help control blood pressure, keep bones healthy and stimulate the production of red blood cells. CKD means that the kidneys have been damaged and filter less effectively for at least three months.

The most common causes are:

• Diabetes, which damages the small blood vessels of the kidneys.
• High blood pressure, which strains the kidney filters over time.
• Glomerulonephritis and other inflammatory or autoimmune kidney diseases.
• Polycystic kidney disease and other inherited conditions.
• Repeated kidney injury, kidney stones, obstruction or long-term use of certain medications.

CKD is classified in stages 1 to 5 according to the estimated glomerular filtration rate (eGFR) and the amount of albumin (protein) in the urine. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK, NIH), many people with early CKD have no symptoms, while later stages can cause fatigue, swelling, shortness of breath, itching, poor appetite and trouble concentrating.

Why CKD is not "curable"

The kidney contains about a million filtering units, called nephrons, in each kidney. When nephrons are destroyed by long-term damage, they are replaced by scar tissue and do not grow back. The remaining nephrons work harder to compensate, which over time can accelerate their own wear. For this reason, the goal of CKD care is to protect the remaining kidney function, slow progression and manage complications. Even the most effective medications slow CKD rather than reverse it.

What regenerative treatment can support

MSCs from Wharton's jelly act through paracrine signaling: they release anti-inflammatory and protective factors that may:

• Reduce chronic inflammation, which contributes to scarring in the kidney.
• Support blood vessel health in the small vessels of the kidney.
• Protect the remaining kidney cells from further injury.
• Limit fibrosis, the scarring that replaces healthy tissue.
• Modulate the immune system, which is especially relevant in inflammatory kidney diseases.

Patients sometimes describe improvements in energy, fatigue and overall well-being. In terms of lab values, the most consistent finding in research is a reduction in protein in the urine, which matters because lower protein leakage is associated with slower progression of kidney disease.

What the evidence shows

Systematic review and meta-analysis (2025)

A review published in Cells analyzed 52 studies of MSCs in CKD, most of them in animal models. In animals, MSCs significantly lowered creatinine, improved filtration and reduced inflammatory markers. The review also included three randomized controlled trials in humans with 86 participants. In both animal and human studies, MSC therapy significantly reduced the urine albumin-to-creatinine ratio. The authors concluded that MSCs show anti-inflammatory and kidney-protective potential.

Safety

Large meta-analyses of IV MSC trials across many conditions, including a 2026 analysis focused on umbilical-cord-derived MSCs in Stem Cells Translational Medicine, found temporary fever to be the most consistent side effect, without an increase in serious infection, thrombosis, cancer or death in controlled trials.

How treatment fits with proven kidney care

The KDIGO 2024 clinical practice guideline for CKD and the NIDDK describe the measures that protect kidney function:

• Blood pressure control, often with ACE inhibitors or angiotensin receptor blockers, which also reduce urine protein.
• Blood sugar control in people with diabetes.
• SGLT2 inhibitors and other kidney-protective medications when appropriate.
• Diet adjustments, including salt and, in some cases, protein and potassium.
• Avoiding kidney-toxic medications, such as regular use of anti-inflammatory painkillers.
• Regular monitoring of eGFR, urine albumin, electrolytes and blood count.

Regenerative treatment is added to these measures. No medication should be stopped because of a regenerative procedure, and your nephrologist remains in charge of your kidney care.

What our patients usually receive

Based on the treatment plans our team prepares for kidney patients, a typical protocol at Stem Cell Mexico includes:

• A review of your recent blood work before the plan is confirmed. The doctor commonly requests creatinine, BUN, albumin, liver enzymes, glucose and HbA1c, iron, lipid panel, uric acid, urinalysis, vitamin D, electrolytes and a renal ultrasound, so the number of cells and the plan fit your current kidney function.
• Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on body weight and medical review, infused slowly and with careful control of fluid volume.
• One night at our facilities with nursing and medical monitoring.
• Consultation with your doctor and the stem cell specialist and ground transportation from the San Diego airport area.

Kidney plans are quoted individually, and the exact figure is confirmed in your written plan. Recovery is gradual, and each person responds differently. Our team stays in contact after treatment and recommends repeating your kidney labs at about one, three and six months, so changes can be compared with your baseline and shared with your nephrologist.

Preparing for treatment with kidney disease

• Bring recent labs and reports: blood work from the past few weeks, your latest urine albumin result, renal ultrasound and a summary from your nephrologist.
• Continue your medications on schedule, including blood pressure and diabetes medications, unless the doctor indicates otherwise.
• Avoid anti-inflammatory painkillers, which can harm the kidneys; paracetamol (acetaminophen) is usually preferred, as the doctor indicates.
• Follow your usual fluid and diet plan during travel, and ask the coordination team about meals during your stay.
• If you are on dialysis, share your dialysis schedule so the visit can be planned around your sessions.
• Travel with a companion if you tire easily or have other health conditions.

Who may be a candidate

• CKD with stable kidney function, without rapid decline or acute kidney injury.
• Controlled blood pressure, safe potassium levels and manageable fluid status.
• Continued care with a nephrologist.
• No active infection and no cancer within the past five years.

People on dialysis and kidney transplant recipients have special considerations. In dialysis, expectations focus on safety and well-being, and treatment is scheduled around dialysis sessions. After a transplant, any regenerative treatment should be discussed with the transplant team first.

Realistic goals

Helpful goals for regenerative treatment in CKD include:

• Lower protein in the urine on follow-up tests.
• Stable eGFR over time.
• Better energy and daily function.
• Continued control of blood pressure and blood sugar.
• Fewer symptoms such as fatigue or swelling, when they are present.

These goals are measured with the same labs used before treatment, which gives you and your nephrologist an objective picture. Writing down how you feel each month, including energy, appetite, sleep and swelling, adds useful information to the lab results.

Warning signs when comparing clinics

Be cautious if a clinic:

• Promises to regenerate your kidneys or help you stop dialysis.
• Claims high success rates without published data.
• Suggests stopping kidney medications.
• Does not ask for recent blood work.
• Says the treatment is risk-free.

Questions to ask during your evaluation

• What stage is my kidney disease, and what is its cause?
• Which labs do you need before confirming the plan?
• How will fluids and blood pressure be managed during the infusion?
• Which tests will we repeat afterward, and when?
• How will you coordinate with my nephrologist?

Bottom line

Stem cell therapy does not cure kidney disease, but it may support the body's repair mechanisms, reduce inflammation and lower protein in the urine, a marker linked to slower progression, with a reassuring safety profile. At Stem Cell Mexico, Wharton's jelly MSCs are given by IV infusion after a review of your blood work, as a complement to nephrology care, with results that vary between individuals and are followed with repeat lab tests. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your kidney condition, goals and medical history.